XOMA Royalty Corporation XOMA R2K
Healthcare · Biotechnology · United States
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
READ MORE ›$41.71
+68.46% 1Y
Market & Price
Market Cap
$523.09M
Current Price
$41.71
High / Low (52W)
$42.00 / $22.89
Beta
0.90
Valuation
Stock P/E
26.57
Industry PE
23.65
Forward P/E
19.49
PEG Ratio
-
Book Value
$7.07
Price to Book
5.90
P/S
10.77
EV/EBITDA
70.14
Dividend Yield
-
Profitability & Returns
ROCE
18.85%
ROE
34.23%
ROA
1.28%
Profit Margin
69.63%
Op Margin
-3.90%
EPS (Latest Qtr)
$0.17
EPS (TTM)
$1.57
Balance Sheet & Liquidity
Debt/Equity
1.10
Quick Ratio
3.31
Current Ratio
3.59
Debt
$124.73M
Total Assets
$272.70M
Current Assets
$117.26M
Working Capital
$82.44M
Ownership
Promoter Holding
4.14%
Chg in Prom Hold
-
FII / Inst Holding
119.86%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$581.79M
Total Revenue (TTM)
$48.55M
EBITDA
$8.29M
Free Cash Flow
$-13.07M
Operating Cash Flow
$6.79M
Shares Outstanding
12.54M
Gross Margin
99.04%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
24.60%
Profit 5Y
95.14%
Revenue (YoY)
-22.60%
Earnings (YoY)
207.90%
PROS
- Strong return on equity of 34.2%.
- Excellent profit margin of 69.6%.
- Compounding revenue at 24.6% over 5 years.
- Profit CAGR of 95.1% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XOMA XOMA Royalty Corporation R2K | 41.71 | 26.57 | $523.09M | - | 18.85% | 34.23% | 24.60% | 95.14% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 10.78M | 36.07M | - | 401.00K | 2.34M | 775.00K | - | 8.03M | 625.00K | 8.53M | - | 500.00K | 53.00K | 200.00K | - | 19.00K | 525.00K | 550.00K | 2.75M | 525.00K | 25.00K | - | 1.12M | 225.00K | 1.00M | 5.03M | - | - | 4.32M | 5.38M | 532.00K | 1.43M | 310.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.61M | 776.00K | 1.86M | -750.00K | 790.00K |
| Operating Income | -23.68M | 28.74M | -13.99M | -18.02M | -12.09M | -17.46M | -10.92M | 1.31M | 28.65M | -2.01M | -5.14M | -2.99M | -5.31M | -3.42M | 1.94M | -4.71M | 2.89M | -4.00M | -5.62M | -3.15M | -2.69M | 23.87M | -6.43M | -3.06M | -3.35M | -2.06M | -4.77M | -4.37M | -10.17M | -5.96M | -5.79M | -7.00M | -10.08M | - | - | 5.93M | 4.60M | -1.33M | 2.18M | -480.00K |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.38M | 13.09M | 18.28M | 10.07M | 8.72M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.47M | 3.24M | 3.30M | 3.03M | 3.36M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.37M | 9.19M | 14.10M | 6.16M | 4.47M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | - | 49.00K | 54.00K | 1.00K |
| Net Income | -480.00K | 25.35M | -8.37M | -15.16M | -12.53M | -17.48M | -10.71M | 285.00K | 26.34M | -1.32M | -3.81M | -1.95M | -4.58M | -3.01M | 3.23M | -4.07M | 3.18M | -4.32M | -4.76M | -3.53M | -1.08M | 22.67M | -7.37M | -2.24M | -4.44M | -2.28M | -4.67M | -4.18M | -9.81M | -5.40M | -5.51M | -8.60M | 15.98M | - | - | 2.37M | 9.19M | 14.05M | 6.10M | 4.46M |
| Diluted EPS | -0.08 | 4.24 | -1.40 | -2.52 | -2.08 | -2.89 | -2.37 | 0.02 | 1.98 | -0.16 | -0.46 | -0.23 | -0.55 | -0.35 | 0.21 | -0.47 | 0.20 | -0.49 | -0.49 | -0.33 | -0.10 | 1.32 | -0.70 | -0.31 | -0.51 | -0.32 | -0.53 | -0.48 | -0.98 | -0.59 | -0.60 | -0.86 | 0.84 | - | - | 0.06 | 0.44 | 0.70 | 0.26 | 0.17 |
| R&D Expense | 17.56M | - | 13.61M | 13.70M | 8.67M | - | 3.99M | 2.92M | 307.00K | - | 432.00K | 376.00K | 637.00K | - | 256.00K | 724.00K | 143.00K | - | 62.00K | 38.00K | 34.00K | - | 61.00K | 38.00K | 30.00K | 56.00K | 40.00K | 29.00K | 54.00K | 39.00K | 25.00K | 33.00K | 1.16M | 817.00K | - | 1.29M | 69.00K | 69.00K | - | 49.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 52.43M | 5.07M | 17.28M | 27.94M | - | 6.03M | 4.76M | 10.22M | 11.66M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 23.44M | 28.22M | 50.20M | 276.00K |
| Operating Income | 12.96M | -67.10M | -33.95M | -56.62M | -58.20M | -81.83M | -39.72M | -61.56M | 17.03M | -16.86M | -3.88M | 12.42M | - | -17.41M | -23.46M | -39.98M | 11.38M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.02M | -39.36M | -5.42M | 47.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 569.00K | 13.84M | 13.03M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.12M | -40.83M | -19.48M | 31.82M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.00K | 0 | -5.66M | 103.00K |
| Net Income | 550.00K | -68.76M | -32.74M | -71.06M | -124.06M | -38.30M | -20.61M | -53.53M | 14.60M | -13.34M | -1.98M | 13.30M | - | -17.10M | -40.83M | -13.82M | 31.71M |
| Diluted EPS | - | - | - | -1.10 | -1.43 | -13.49 | -3.50 | -8.89 | 0.73 | -1.59 | -0.23 | 0.78 | - | -1.98 | -4.04 | -1.65 | 1.46 |
| R&D Expense | 58.13M | 77.41M | 68.14M | 68.47M | 74.85M | 80.75M | 70.85M | 44.23M | 7.88M | 1.68M | 1.25M | 170.00K | 171.00K | 153.00K | 143.00K | 2.88M | 1.71M |
Compounded Sales Growth
| 5 Years: | 24.60% |
| 1 Year: | -22.60% |
Compounded Profit Growth
| 5 Years: | 95.14% |
| 1 Year: | 207.90% |
Stock Price Performance
| 1 Year: | +68.46% |
| 6 Months: | +30.96% |
| 3 Months: | +63.38% |
| 1 Month: | +1.76% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 74.25M | 78.04M | 105.68M | 134.78M | 89.40M | 74.88M | 28.68M | 44.94M | 63.78M | 95.72M | 125.28M | - | 140.38M | 234.30M | 221.28M | 272.70M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.25M | 169.31M | 125.60M | 117.26M |
| Cash & Equivalents | 9.51M | 23.91M | 37.30M | 48.34M | 45.34M | 101.66M | 78.44M | 65.77M | 25.74M | 43.47M | 45.78M | - | - | - | 57.83M | 153.29M | 101.65M | 82.91M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00K | 1.00M | 1.84M | 4.90M |
| Total Liabilities | - | - | 50.66M | 63.02M | 84.21M | 138.77M | 86.30M | 77.19M | 75.89M | 39.15M | 45.00M | 51.74M | 38.86M | - | 16.37M | 145.58M | 159.38M | 188.76M |
| Current Liabilities | - | - | 35.53M | 20.63M | 23.83M | 29.64M | 36.25M | 23.30M | 32.51M | 7.42M | 5.70M | 8.88M | 12.30M | - | 6.82M | 19.50M | 24.37M | 34.82M |
| Long Term Debt | - | - | 13.69M | 33.52M | 37.65M | 35.15M | 16.29M | 42.76M | 25.31M | 14.57M | 21.69M | 27.09M | 12.76M | - | - | 118.52M | 106.88M | 96.45M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.00K | 124.45M | 119.20M | 131.56M |
| Total Equity | -31.40M | 17.53M | 23.59M | 15.01M | 21.47M | -3.99M | 3.10M | -2.31M | -47.21M | 5.79M | 18.79M | 43.99M | 86.42M | - | 124.01M | 88.72M | 61.90M | 83.94M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.45M | 11.50M | 11.95M | 11.86M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 7.43M | -52.54M | -29.06M | -40.77M | -45.91M | - | - | - | 2.69M | -12.64M | -285.00K | 10.09M | - | -12.88M | -18.16M | -13.75M | 2.87M |
| Investing Cash Flow | 10.57M | -339.00K | -3.30M | -42.02M | 18.84M | - | - | - | 1.61M | -15.01M | -19.30M | -209.00K | - | -20.22M | -711.00K | -28.26M | 50.89M |
| Financing Cash Flow | -3.61M | 66.27M | 43.98M | 79.78M | 83.39M | - | - | - | 13.26M | 29.94M | 30.49M | 19.79M | - | -4.45M | 120.59M | -11.13M | -26.46M |
| Capital Expenditure | -270.00K | -339.00K | -3.30M | -2.51M | -1.17M | -325.00K | -430.00K | -59.00K | -8.00K | -6.00K | - | -9.00K | - | -15.25M | -17.00K | -20.00K | -20.73M |
| Free Cash Flow | 7.17M | -52.88M | -32.37M | -43.27M | -47.08M | - | - | - | 2.68M | -12.65M | - | 10.08M | - | -28.13M | -18.18M | -13.77M | -17.85M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -37.55M | 101.72M | -53.13M | 27.29M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.00K | 16.04M |
| Dividends Paid | - | - | - | - | - | - | - | - | - | - | - | - | 3.50M | 5.47M | 5.47M | 5.47M | 5.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | 32.5% | -332.6% | -22.5% | 44.4% | - | -288.9% | -493.1% | -391.2% | 97.6% |
| Net Margin % | - | - | - | - | - | - | - | - | 27.8% | -263.3% | -11.5% | 47.6% | - | -283.8% | -858.2% | -135.2% | 272.0% |
| ROE % | 3.1% | -291.5% | -218.1% | -331.0% | 3,111.6% | -1,235.9% | 892.4% | 113.4% | 252.3% | -71.0% | -4.5% | 15.4% | - | -13.8% | -46.0% | -22.3% | 37.8% |
| ROCE % | - | -173.3% | -59.1% | -69.2% | -55.4% | -153.9% | -77.0% | 1,607.7% | 45.4% | -29.0% | -4.5% | 11.0% | - | -13.0% | -10.9% | -20.3% | 4.8% |
Shareholding Pattern
Insiders
4.14%
Institutions
119.86%
Public Float
125.03%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | BVF Inc. | 20.65% | 2.59M | $108.04M |
| 2 | Morgan Stanley | 13.57% | 1.70M | $71.00M |
| 3 | FMR, LLC | 10.39% | 1.30M | $54.35M |
| 4 | Blackrock Inc. | 5.16% | 646.91K | $26.98M |
| 5 | Woodline Partners LP | 5.10% | 640.00K | $26.69M |
| 6 | Vanguard Capital Management LLC | 4.38% | 549.80K | $22.93M |
| 7 | Opaleye Management Inc. | 2.39% | 300.00K | $12.51M |
| 8 | GW&K Investment Management, LLC | 1.85% | 232.14K | $9.68M |
| 9 | Geode Capital Management, LLC | 1.83% | 229.77K | $9.58M |
| 10 | Millennium Management Llc | 1.63% | 204.92K | $8.55M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XOMA
No recent headlines available.